How can small firms benefit from open innovation? The case of new drug development in Taiwan Online publication date: Fri, 25-Nov-2016
by Yu-Shan Su; Hsin-Yi Hu; Feng-Shang Wu
International Journal of Technology Management (IJTM), Vol. 72, No. 1/2/3, 2016
Abstract: How can small firms manage and benefit from open innovation? We study three Taiwan's biotechnology firms leveraging open innovation in developing new drugs. At the phase of the new drug discovery, two companies acquired technology from external sources. CSRC Synpac Company acquired technology from Professor Yuan-Tsong Chen at Duke University (USA) in 1991. GlycoNex Company acquired technology from Professor Sen-itiroh Hakomori at University of Washington (USA) in 2001. AbGenomics Company developed its own technology at Professor Rong-Hwa Lin's team at National Taiwan University (Taiwan) in 2000. Through technology transfer, CSRC Synpac Company licensed out the new drug Myozyme to Genzyme Corporation (USA) in 2000. AbGenomics Company licensed out the new drug AbGn-168H to Boehringer Ingelheim Pharmaceutical (Germany) in 2005. GlycoNex Company licensed out the new drug GNX-8 to Otsuka Pharmaceutical (Japan) in 2009.
Online publication date: Fri, 25-Nov-2016
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Management (IJTM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.If you still need assistance, please email email@example.com